Star Imaging and Path Lab Ltd
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company providing diagnostic services across a wide range of medical tests.[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 70.1
- High / Low ₹ 152 / 46.0
- Stock P/E 6.32
- Book Value ₹ 66.6
- Dividend Yield 0.00 %
- ROCE 26.2 %
- ROE 23.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.05 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 212 days.
- Working capital days have increased from 97.9 days to 146 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 69 | 58 | 78 | 82 | 86 | |
| Sales growth | -15% | +34% | +4% | +5% | |
| 54 | 52 | 56 | 53 | 53 | |
| Operating Profit | 15 | 6 | 23 | 29 | 33 |
| OPM % | 21% | 10% | 29% | 35% | 39% |
| 0 | 0 | 1 | 0 | 1 | |
| Interest | 2 | 2 | 2 | 3 | 2 |
| Depreciation | 4 | 3 | 5 | 5 | 6 |
| Profit before tax | 9 | 1 | 16 | 21 | 26 |
| Tax % | 33% | 34% | 23% | 25% | 27% |
| 6 | 1 | 12 | 16 | 19 | |
| EPS in Rs | 4.67 | 0.42 | 9.14 | 11.79 | 11.09 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 224% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -51% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 32% |
| Last Year: | 24% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 14 | 17 |
| Reserves | 17 | 17 | 30 | 34 | 99 |
| 30 | 27 | 31 | 33 | 21 | |
| 10 | 16 | 19 | 18 | 17 | |
| Total Liabilities | 58 | 61 | 81 | 98 | 153 |
| 15 | 19 | 22 | 21 | 25 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 43 | 42 | 60 | 77 | 128 | |
| Total Assets | 58 | 61 | 81 | 98 | 153 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 14 | 6 | 18 | -2 | 23 | |
| -4 | -9 | -7 | -7 | -13 | |
| -7 | -5 | 2 | -0 | 36 | |
| Net Cash Flow | 3 | -7 | 13 | -10 | 46 |
| Free Cash Flow | 10 | -2 | 11 | -7 | 13 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 115% | 115% | 98% | 10% | 91% |
Ratios
Standalone / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 86 | 110 | 151 | 227 | 212 |
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | 86 | 110 | 151 | 227 | 212 |
| Working Capital Days | 6 | -12 | 23 | 124 | 146 |
| ROCE % | 6% | 33% | 34% | 26% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| B2C Revenue Share % |
|
||||
| Number of Diagnostic Centers centers |
|||||
| Total Tests Conducted tests |
|||||
| CT Scans Performed tests |
|||||
| MRI Scans Performed tests |
|||||
| Pathology Tests Performed tests |
|||||
| Team Size employees |
|||||
| B2B Hospital Tie-ups tie-ups |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Investor meet for the Half Year Ended September 30, 2026.
-
Board Meeting Intimation for To Consider And Approve Unaudited (Standalone And Consolidated) Financial Results Of The Company For The Half Year Ended September 30, 2026
- Board meeting on 13 November 2026 to approve unaudited half-year results for September 30, 2026.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Empanelment With MCD
- Empanelled with MCD to provide diagnostic services at CGHS rates.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Compliance Certificate as per Regulation 74(5) of SEBI ( Depositories and Participants) Regulations, 2018 for the Quarter ended 30th September 2026
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 22nd AGM voting results and scrutinizer report filed; two ordinary resolutions passed on 29 September 2026.
Concalls
-
May 2026Transcript PPT
Business Profile:[1]
Star Imaging and Path Lab Limited,
formerly known as Janta X-Ray Clinic,
is a Delhi-headquartered diagnostic
healthcare service provider accredited
by NABL and NABH. It offers pathology,
radiology, cardiology, and neurology
services across Delhi, Uttar Pradesh,
and Nashik, Maharashtra.
As of FY26, it runs 24 diagnostic centres
with a team of 236 people and conducted
7.1 lakh tests during the year